Atossa Therapeutics
Open
$5.30
Prev. Close
$5.30
High
$5.43
Low
$5.30
Market Snapshot
$45.47M
-1.3
-3.15
16
Atossa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
emptyResult
Atossa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Recently from Cashu
Atossa Therapeutics Strengthens Leadership to Accelerate Oncology and Rare Disease Treatment Development
Atossa Therapeutics Enhances Clinical Leadership to Advance Targeted Therapies Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical firm renowned for developing innovative treatments for onco…
Atossa Therapeutics' (Z)-Endoxifen Shows Promise for Duchenne Muscular Dystrophy Treatment
Atossa Therapeutics Expands Hope for Duchenne Muscular Dystrophy with (Z)-Endoxifen Atossa Therapeutics, Inc. recently garners attention in the biopharmaceutical sector with its presentation at the MD…
Atossa Therapeutics Highlights Promising Results for DMD Therapy (Z)-endoxifen at MDA Conference
Atossa Therapeutics Advances Promising DMD Therapy Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, showcases significant advancements in its investigational therapy, (Z)-endoxif…
Atossa Therapeutics' (Z)-endoxifen Shows Promising Potential in Duchenne Muscular Dystrophy Treatment
Promising Advances in DMD Treatment: Atossa Therapeutics' (Z)-endoxifen Shows Potential Atossa Therapeutics, Inc. presents exciting findings regarding its investigational therapy, (Z)-endoxifen, at th…